Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.